Gene · 27329
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Robust and adaptive non-parametric tests for detecting general distributional shifts in gene expression. | Cell Rep Methods | 2025 | 40902592 | PubTator, text mining | PubMed |
| Exploring the relationship between lipid-lowering drug target genes and sensorineural hearing loss by Mendelian randomization. | Medicine (Baltimore) | 2025 | 40898542 | PubTator, text mining | PubMed |
Letter by Shi et al Regarding Article "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality". | Circulation | 2025 | 40892888 | PubTator, text mining | PubMed |
Response by Silbernagel et al to Letters Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality". | Circulation | 2025 | 40892885 | PubTator, text mining | PubMed |
Letter by Huang Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality". | Circulation | 2025 | 40892883 | PubTator, text mining | PubMed |
| A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part II. | Pharmaceuticals (Basel) | 2025 | 40872541 | PubTator, text mining | PubMed |
| Multimodal Therapy Achieves Secondary Prevention LDL-C Targets in LDL-Receptor Null Homozygous Familial Hypercholesterolemia. | JACC Case Rep | 2025 | 40846360 | PubTator, text mining | PubMed |
| Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation. | Med Sci (Basel) | 2025 | 40843747 | PubTator, text mining | PubMed |
| PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs. | Open Heart | 2025 | 40841123 | PubTator, text mining | PubMed |
| Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study. | Atherosclerosis | 2025 | 40839980 | PubTator, text mining | PubMed |
| Multivariate genome-wide association analysis of dyslexia and quantitative reading skill improves gene discovery. | Transl Psychiatry | 2025 | 40825760 | PubTator, text mining | PubMed |
| Associations of ANGPTL proteins and complexes with progression of coronary artery calcification and coronary events. | Atherosclerosis | 2025 | 40819411 | PubTator, text mining | PubMed |
| The proteogenomic landscape of the human kidney and implications for cardio-kidney-metabolic health. | Nat Med | 2025 | 40796935 | PubTator, text mining | PubMed |
| International Validation of Risk Scores for Familial Hypercholesterolemia. | Can J Cardiol | 2025 | 40782838 | PubTator, text mining | PubMed |
| Lipid-lowering drug targets influence inflammatory bowel disease through gut microbiota and inflammatory cytokines. | J Lipid Res | 2025 | 40769382 | PubTator, text mining | PubMed |
| Outpatient monthly plasmapheresis with post-PLEX evinacumab in pediatric homozygous familial hypercholesterolemia: a case report on port access and immunoglobulin preservation. | Front Pediatr | 2025 | 40755922 | PubTator, text mining | PubMed |
| Recent Advances in Medications for Reducing Lipid Levels. | Cardiol Rev | 2025 | 40745448 | PubTator, text mining | PubMed |
| Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. | Diabetes Obes Metab | 2025 | 40726454 | PubTator, text mining | PubMed |
| Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study. | Circ Genom Precis Med | 2025 | 40718904 | PubTator, text mining | PubMed |
| Identification of protein targets for dyslipidaemia and cardiovascular diseases among people with South Asian ancestry: a mendelian randomisation study. | Lancet Reg Health Southeast Asia | 2025 | 40689090 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27329/papers?page=10